{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T01:40:14Z","timestamp":1758937214832,"version":"3.44.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2015,3,1]],"date-time":"2015-03-01T00:00:00Z","timestamp":1425168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,3,1]],"date-time":"2015-03-01T00:00:00Z","timestamp":1425168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"GECOM association"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2015,3]]},"DOI":"10.1016\/j.leukres.2014.11.014","type":"journal-article","created":{"date-parts":[[2014,12,13]],"date-time":"2014-12-13T11:01:19Z","timestamp":1418468479000},"page":"329-334","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Phosphorylation of spleen tyrosine kinase at tyrosine 348 (pSyk348) may be a marker of advanced phase of Chronic Myeloid Leukemia (CML)"],"prefix":"10.1016","volume":"39","author":[{"given":"C\u00e9line","family":"Bourgne","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandre","family":"Janel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juliette","family":"Berger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chantal","family":"Rapatel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Tournilhac","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Hermet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agn\u00e8s","family":"Guerci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fr\u00e9d\u00e9rique","family":"Lioret","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aur\u00e9lie","family":"Brian\u00e7on","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahchid","family":"Bamdad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathalie","family":"Boiret-Dupr\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc G.","family":"Berger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2014.11.014_bib0005","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/243290a0","article-title":"Letter A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining","volume":"243","author":"Rowley","year":"1973","journal-title":"Nature"},{"key":"10.1016\/j.leukres.2014.11.014_bib0010","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/0092-8674(84)90438-0","article-title":"An alteration of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine kinase activity","volume":"37","author":"Konopka","year":"1984","journal-title":"Cell"},{"key":"10.1016\/j.leukres.2014.11.014_bib0015","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1182\/blood-2010-10-313692","article-title":"Quantitative phosphoproteomics revealed interplay between Syk and Lyn in the resistance to nilotinib in chronic myeloid leukemia cells","volume":"118","author":"Gioia","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2014.11.014_bib0020","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/j.bbrc.2005.01.076","article-title":"Protein-tyrosine kinase, Syk, is required for CXCL12-induced polarization of B cells","volume":"328","author":"Matsusaka","year":"2005","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.leukres.2014.11.014_bib0025","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1038\/ni1407","article-title":"Integrin signaling in neutrophils and macrophages uses adaptors containing immunoreceptor tyrosine-based activation motifs","volume":"7","author":"M\u00f3csai","year":"2006","journal-title":"Nat Immunol"},{"key":"10.1016\/j.leukres.2014.11.014_bib0030","doi-asserted-by":"crossref","first-page":"16597","DOI":"10.1074\/jbc.271.28.16597","article-title":"Syk tyrosine kinase is required for immunoreceptor tyrosine activation motif-dependent actin assembly","volume":"271","author":"Cox","year":"1996","journal-title":"J Biol Chem"},{"key":"10.1016\/j.leukres.2014.11.014_bib0035","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1182\/blood-2004-12-4918","article-title":"Small peptide inhibitors of the CXCR4 chemokine receptor (CD184) antagonize the activation, migration, and antiapoptotic responses of CXCL12 in chronic lymphocytic leukemia B cells","volume":"106","author":"Burger","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2014.11.014_bib0040","doi-asserted-by":"crossref","first-page":"L497","DOI":"10.1152\/ajplung.00246.2004","article-title":"Syk tyrosine kinase participates in beta1-integrin signaling and inflammatory responses in airway epithelial cells","volume":"288","author":"Ulanova","year":"2005","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"10.1016\/j.leukres.2014.11.014_bib0045","doi-asserted-by":"crossref","first-page":"22155","DOI":"10.1074\/jbc.M808182200","article-title":"Depletion of Pleckstrin homology domain leucine-rich repeat protein phosphatases 1 and 2 by Bcr\u2013Abl promotes chronic myelogenous leukemia cell proliferation through continuous phosphorylation of Akt isoforms","volume":"284","author":"Hirano","year":"2009","journal-title":"J Biol Chem"},{"key":"10.1016\/j.leukres.2014.11.014_bib0050","doi-asserted-by":"crossref","first-page":"4497","DOI":"10.1182\/blood-2009-07-233692","article-title":"Spleen tyrosine kinase inhibition prevents chemokine- and integrin-mediated stromal protective effects in chronic lymphocytic leukemia","volume":"115","author":"Buchner","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2014.11.014_bib0055","doi-asserted-by":"crossref","first-page":"6151","DOI":"10.1093\/emboj\/16.20.6151","article-title":"Transformation of hematopoietic cells by BCR\/ABL requires activation of a PI-3k\/Akt-dependent pathway","volume":"16","author":"Skorski","year":"1997","journal-title":"EMBO J"},{"key":"10.1016\/j.leukres.2014.11.014_bib0060","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1002\/cyto.a.22118","article-title":"Measurement of imatinib uptake by flow cytometry","volume":"81","author":"Bourgne","year":"2012","journal-title":"Cytometry A"},{"key":"10.1016\/j.leukres.2014.11.014_bib0065","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1182\/blood.V99.1.319","article-title":"Primitive, quiescent, philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro","volume":"99","author":"Graham","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2014.11.014_bib0070","doi-asserted-by":"crossref","first-page":"4016","DOI":"10.1182\/blood-2006-11-057521","article-title":"Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells","volume":"109","author":"J\u00f8rgensen","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2014.11.014_bib0075","doi-asserted-by":"crossref","first-page":"4532","DOI":"10.1182\/blood-2005-07-2947","article-title":"Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction","volume":"107","author":"Copland","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2014.11.014_bib0080","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1158\/1078-0432.CCR-09-1519","article-title":"Activities of SYK and PLCgamma2 predict apoptotic response of CLL cells to SRC tyrosine kinase inhibitor dasatinib","volume":"16","author":"Song","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.leukres.2014.11.014_bib0085","doi-asserted-by":"crossref","first-page":"5276","DOI":"10.4049\/jimmunol.161.10.5276","article-title":"Syk- and Lyn-dependent phosphorylation of Syk on multiple tyrosines following B cell activation includes a site that negatively regulates signaling","volume":"161","author":"Keshvara","year":"1998","journal-title":"J Immunol"},{"key":"10.1016\/j.leukres.2014.11.014_bib0090","doi-asserted-by":"crossref","first-page":"3852","DOI":"10.1002\/cncr.25123","article-title":"Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a phase 3 study: efficacy and tolerability of 140 milligrams once daily and 70 milligrams twice daily","volume":"116","author":"Saglio","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2014.11.014_bib0095","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1016\/j.clinthera.2007.11.005","article-title":"Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"29","author":"Steinberg","year":"2007","journal-title":"Clin Ther"},{"key":"10.1016\/j.leukres.2014.11.014_bib0100","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"362","author":"Kantarjian","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2014.11.014_bib0105","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1124\/jpet.106.109058","article-title":"R406, an orally available spleen tyrosine kinase inhibitor blocks Fc receptor signaling and reduces immune complex-mediated inflammation","volume":"319","author":"Braselmann","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.leukres.2014.11.014_bib0110","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.3748\/wjg.v10.i12.1815","article-title":"Hypermethylation of Syk gene in promoter region associated with oncogenesis and metastasis of gastric carcinoma","volume":"10","author":"Wang","year":"2004","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.leukres.2014.11.014_bib0115","doi-asserted-by":"crossref","first-page":"6687","DOI":"10.1158\/1078-0432.CCR-06-0921","article-title":"Frequent epigenetic inactivation of spleen tyrosine kinase gene in human hepatocellular carcinoma","volume":"12","author":"Yuan","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.leukres.2014.11.014_bib0120","doi-asserted-by":"crossref","first-page":"3889","DOI":"10.1182\/blood-2012-09-457887","article-title":"\u03b22 integrin-derived signals induce cell survival and proliferation of AML blasts by activating a Syk\/STAT signaling axis","volume":"121","author":"Oellerich","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2014.11.014_bib0125","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1038\/leu.2013.89","article-title":"SYK regulates mTOR signaling in AML","volume":"27","author":"Carnevale","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2014.11.014_bib0130","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.ccr.2009.08.018","article-title":"Proteomic and genetic approaches identify Syk as an AML target","volume":"16","author":"Hahn","year":"2009","journal-title":"Cancer Cell"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014521261400366X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014521261400366X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T00:58:43Z","timestamp":1758934723000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S014521261400366X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,3]]}},"alternative-id":["S014521261400366X"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2014.11.014","relation":{},"ISSN":["0145-2126"],"issn-type":[{"type":"print","value":"0145-2126"}],"subject":[],"published":{"date-parts":[[2015,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phosphorylation of spleen tyrosine kinase at tyrosine 348 (pSyk348) may be a marker of advanced phase of Chronic Myeloid Leukemia (CML)","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2014.11.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}